Through modification of the protocol by Adams, we developed a biotin amplification procedure for immunofluorescence staining of immediate early gene proteins and also applied biotin amplification for metal enhancement of diaminobenzidine staining in an immunoperoxidase protocol. Commercially available antidos antisera were used to compare conventional "Elite" avidin-biotin complex reactions with biotin amplification reactions (visualized with peroxidase staining or streptavidin-Texas Red fluorescence). Biotin amplification and peroxidase staining (with or without nickel salts) enabled detection of 6 0 s in stimulated neurons with primary antibody concentrations fiveto tenfold lower than the conventional procedure. With immunofluorescence staining, at primary antibody concentrations too low
Introduction
Initial studies conducted in 1988 determined that immunostaining of the immediate early gene product cFos represents a potentially powerful anatomic tool for identifying activated neurons (1). Most neurons express little or no cFos under baseline conditions. However, in response to a variety of stimuli, neurons rapidly express the cFos protein. Subsequent investigations have substantiated the utility of cFos staining for labeling activated neurons under a variety of stimulated conditions (2-10). Increased sensitivity and enhancement of immunocytochemical methods for the localization of the immediate early gene product cFos would be of great benefit. Such an achievement would provide a great many investigators with an even more powerful tool with which to monitor neuronal activation. In a recent report, Adams (11) devised a method of biotin amplification for immunohistochemistry, lectin histochemistry, and for neuroanatomic tracing methods. In immunocytochemical applications, biotin amplification lowered the concentration of primary antibody required for optimal immunostaining and intensified the immunohistochemical signals. The biotin amplification method is based on use of immunoperoxidase to detect CFOS with the conventional biotin-streptavidin fluorescence staining protocol, biotin amplification enabled clear 8 0 s fluorescence staining with both antisera. The fluorescence staining exhibited a high signal-to-noise ratio and enabled antibody concentrations four times lower than those used for conventional ABC "Elite" peroxidase procedures. In conclusion, the application of biotin amplifcation to CFOS immunocytochemical localization has the pmmise of aiding the scientist in detecting these immediate early gene products. (JH&" procedures coupled with a substrate for peroxidase (biotinylated tyramine) that, when oxidized in the presence of peroxide as a cosubstrate, deposits a source of biotin. The biotin is further reacted with avidin coupled to peroxidase, thus greatly increasing the amount of enzyme available for chromogen reaction. According to Adams, the protocol was not compatible with nickel-cobaltenhanced immunostaining because it resulted in greatly increased background staining, presumably due to the difficulty in controlling the rate of the peroxidase reaction in the presence of the metal. Nevertheless, the Adams report provided the theoretical foundation for applying the biotin amplification procedure to cFos immunocytochemical localization to increase visibility of the nuclear protein product. Specifically, the objectives of this study were to apply biotin amplification to ABC "Elite" peroxidase procedures with nickel-enhanced diaminobenzidine (DAB) as the chromogen for immunocytochemical staining of cFos and to apply it to test whether biotin amplification could improve ABC fluorescence procedures as well.
Materials and Methods
Brain tissue was obtained from male Sprague-Dawley tats (Zivic Miller; Zelienople, PA) weighing approximately 250-300 g. The basic procedure we used to stimulate cFos expression in this study was derived from previous studies describing strong cFos induction after IP injection of hypertonic saline (12). Each animal received 2 ml of 2 M NaCl IP; controls received BERGHORN, BONNETI, HOFFMAN an equal volume of isotonic saline or were untreated. Injection of hypertonic saline elicits strong CFOS induction in magnocellular neurons of the supraoptic nucleus (SON) and paraventricular nucleus (PVN) in the hypothalamus of the rat forebrain; these areas express no CFOS under baseline conditions or after isotonic saline injections. One hr after injection, each rat was administered an overdose of sodium pentobarbital (100 mglkg, IP).
Perfusion
Each rat was perfused transcardially first with saline containing 2 % sodium nitrite followed by 2.5% acrolein (EM grade; Polysciences, Warrington, PA) in 4% paraformaldehyde in 0.1 M potassium phosphate-buffered saline (KPBS), pH 6.8, and a second saline rinse, as previously described (12). After fixation the brain was removed and the hypothalamus blocked. The hypothalamus was immersed for 24-48 hr in 25% aqueous sucrose until it sank. The brain was then cut into 25-pm thick sections with a Reichert freezing (sliding) microtome. Tissue sections were stored in cryoprotectant solution (13) at -20°C until they were processed for immunostaining.
Immunocytochemistry
Conventional Immunoperoxidase Staining. Our basic immunocytochemical procedures have been described previously (14). For immunoperoxidase staining we used the reagents of the ABC "Elite" kits (Vector; Burlingame, CA), but the procedures were modified slightly over the protocol provided by the manufacturer. Briefly, the steps were:
1. Tissue sections were thoroughly rinsed (10 washes over 60 min) with 0.05 M KPBS, pH 7.4, to remove cryoprotectant. 2. Sections were then incubated in sodium borohydride (1% w/v KPBS) for 20 min. followed by rinsing multiple times until no bubbles remained. The sodium borohydride partially neutralizes the acrolein that prevents reactive aldehydes from causing nonspecific staining.
3.
The primary antibody diluted in 0.05 M KPBS + 0.4% Triton X-100 was applied to the tissue for 1 hr at room temperature (RT), then incubated at 4°C for 48 hr. 4. After 48 hr sections were rinsed 10 times over 60 min with 0.05 M KPBS to remove primary antibody. 5. Tissue was placed in biotinylated goat anti-rabbit IgG (Vector) 1:600 in 0.05 M KPBS + 0.4% Triton X-100 for 1 hr at RT.
6.
Sections were rinsed eight times over 45 min in 0.05 M KPBS. 7. Sections were transferred to AB solution (45 p1 A and 45 pl B in 10 ml KPBS + 0.4% Triton X-100; ABC "Elite" kit) for 60 min. The AB solution was made 30 min before use. 8. Sections were rinsed initially with KPBS, then 0.05 M Tris buffer, pH 7.2, for DAB staining or 0.175 M sodium acetate for nickel-DAB staining. Tissue was stained for 2-10 min (precise times were determined empirically). The DAB solution was prepared using 0.002 g DAB (Fluka;
Ronkonkoma, NY) and 8.3 p1 3% H202 in 10 ml Tris buffer; nickel sulfate-DAB chromogen solution was prepared using 0.002 g DAB, 0.250 g nickel sulfate (Sigma; St Louis, MO), and 8.3 pl 3Oh H202 in 10 ml sodium acetate solution. After final rinsing in the appropriate buffer to stop the reaction, sections were rinsed briefly in KPBS, mounted with isotonic saline onto subbed glass slides, dehydrated through several concentrations of alcohols, and coverslipped with Histomount (National Diagnostics; Manville, NJ).
Biotin Amplificaton Immunoperoxidase Staining. Steps 1-4 were identical to the conventional immunoperoxidase protocol.
.
Tissue was then transferred to biotinylated goat anti-rabbit IgG at a reduced concenuation (15000 in KPBS + 0.4% Triton x-100) for 1 hr at RT.
6.
Sections were rinsed eight times over 45 min in KPBS before transfer to a more dilute AB solution (22.5 pl A and 22.5 pl B in 10 ml KPBS + 0.4% Triton X-100) for 30 min. The AB solution was made 30 min before use. Tissue was again rinsed multiple times and then incubated in biotinylated tyramine (BT; 1 pl BTIml KPBS + 0.005% H202) for 20 min. BT (DuPont NEN; Wilmington, DE) is a reagent in their BLAST (Blotting Amplification System for HRP Detection); we also used BT generated in our laboratory by the method described by Adams (11), which gave comparable results at concentrations of 10 pUm1. After thorough rinsing, sections were incubated for 1 hr at 37'C in AB solution (11.25 p1 A and 11.25 pl B in 10 ml of warm KPBS + 0.4%
Triton X-100). Sections were rinsed as described for the conventional immunoperoxidase procedure. Tissue was stained with DAB or nickel sulfate-DAB chromogen solution for 2-10 min. The dilute DAB solution was prepared using 0.002 g DAB and 8.3 pI 3% H202 in 40 ml Tris buffer; the dilute nickel sulfate-DAB chromogen solution was prepared using 0.002 g DAB, 0.250 g nickel sulfate, and 8.3 pl 3% H202 in 40 ml sodium acetate. After final rinsing in the appropriate buffer to stop the reaction, sections were processed as outlined for the conventional immunoperoxidase protocol.
Conventional Immunofluorescence Staining. This procedure was performed as described previously (4). Briefly: Steps 1-4 were identical to-the conventional immunoperoxidase protocol.
5. Tissue was placed in biotinylated goat anti-rabbit IgG (1:600 in 0.05 M 6. Sections were rinsed eight times over 45 min in KPBS. 7. Tissue sections were incubated in Ts;as Red-streptavidm (Biomeda; Foster City, CA) at 37'C for 3 hr. Texas Red-streptavidin was used at a concentration of 10 pl/ml in pre-heated 0.05 M KPBS + 0.4% Triton X-100.
8. Tissue was rinsed in KPBS eight times over 45 min, transferred to isotonic saline, mounted on subbed glass slides, and air-dried overnight (taking care not to expose sections to light for prolonged periods of time).
KPBS + 0.4% Triton X-100) for 1 hr at RT. 9. Slides were cleared in xylenes and coverslipped with Histomount.
Biotin Amplification Immunofluorescence Staining. Steps 1-4 were identical to the conventional immunoperoxidase protocol.
Sections were incubated in biotinylated goat anti-rabbit IgG at 1:5000 in KPBS + 0.4% Triton X-100 for 1 hr at RT.
Tissue was rinsed multiple times in KPBS, then transferred to AB solution (11.25 pI A and 11.25 p1 B in 10 ml of KPBS + 0.4% Triton X-100)
for 30 min at RT. This was followed by rinsing eight times over 45 min and then sections were transferred to BT (5-10 pl BT/ml KPBS + 0.005% H202) for 20 min at RT. Sections were thoroughly rinsed to remove excess BT, then incubated at 37°C for 3 hr with Txas Red-streptavidin at a concentration of 5 pl/ml in heated KPBS + 0.4% Triton X-100. Tissue was then processed as described for conventional immunofluorescence.
Primary Antibodies
In comparing the various immunocytochemical procedures we used two commercially available CFOS antisera and a wide range of primary antiserum concentrations. Both antibodies had been screened previously in our laboratory using the nickel-DAB chromogen and the conventional ABC "Elite" procedure. For the Santa Cruz #4 antibody (Santa Cruz Biotechnology; Santa Cruz, CA), initial screening with concentrations ranging from 1:500 to 1:100,000 determined that the optimal concentration lay close to 1:10,000. Therefore the Santa CNZ antiserum tests of the efficacy of the biotin amplification method began with a concentration of 1:5000 and extended to 1:800,000. Similarly, the Oncogene Science (Cambridge, MA) antibody had A been screened with the conventional method long before rhisstudy began. I t s optimal range was approximately 1:45.000. We began our investigations of biotin amplification with concentrations of the Oncogene Science antibody of 1:30.000 and extended the concentrations to 1:200.000. For each method comparison. adjacent sections from the same rat were used. For the purpose of simplicity. results will be illustrated with respect to the SON only.
Results
As expected. treatment of rats with hypertonic saline resulted in strong induction of cFos immunoreactivity in both the SON and the PVN hypothalamic nuclei detected with either antibody and our conventional ABC-peroxidase staining method (Figure 1) . Staining the tissue with DAB alone or nickel-DAB did not alter the sensitivity of the staining reaction. but the nickel-DAB chromogen provided greater contrast between the stained nuclei and the tissue background. making the nickel-DAB appear more sensitive.
Titration of the two primary antisera verified that the optimal concentration had remained as first determined. For the Santa Cruz #4 antibody. a 1:500 dilution was too concentrated to detect cFos in the SON, and the optimal concentration was 1:lO.OOO. with a decline in cFos intensity at 1:100,000 ( Figure 2) . When the biotin amplificationhickel-DAB chromogen procedure was employed, Santa Cruz anti-cFos #4 immunoreactivity was detected at a much lower concentration than that of the conventional ABC-peroxidase method, i.e.. cFos staining was visible at primary antibody concentrations of 1:100.000 and 1:800,000 (Figure 2) . At a concentration of 1:800.000, the staining of cFos was still evident. although fcwcr nuclei were detected and background staining was increased.
The Oncogene Science anti-cFos antibody produced optimal results at a dilution of 1:45,000, with only a slight decline in intensity noticeable at 1:100,000 using our conventional protocol. As with the Santa Cruz antiserum, the highest concentration did not cnable visualization of cFos-positive nuclei (Figure 3 ). Oncogene Science anti-cFos immunostaining with the biotin amplificationhickel-DAB chromogen also extended the range in which cFos could be detected. Clear cFos immunoreactivity could be detected after biotin amplification at dilutions of the primary antibody of 1:200.000. and that range could probably have been further extended ( Figure 3 ). Biotin amplification did not markedly increase background staining at any of the concentrations rated. Additional lots of the Oncogene Science anti-cFos antibody were tested and yielded similar results.
Biotin amplification in conjunction with immunofluorescence now enabled detection of cFos immunoreactivity at concentrations of primary antibodies that produced no signal with the conven- the biotin amplification procedure could abruptly fail. Other studies tional technique. Santa Cruz anti-cFos #4 showed clear immunofluorescence of nuclear cFos at concentrations of 1:lO.OOO and were being conducted in the laboratory at the same time. which used either the same primary antibody and staining without am-1:30,000, with no significant background staining (Figure 4) . The
Oncogene Science antibody also produced a detectable signal at plification or amplification with primary antibodies and either the peroxidax or fluorescence visualization proce-concentrations similar to those effective with the biotin amplificationhickel-DAB chromogen ( Figure 5 ). Although we did not meadures. All amplification appeared to fail at once. In determining sure the intensity of the fluorescence signals, the amplified Onthe source of the failure. we noted that the commercially available BT was at fault. If BT from a new kit was used. the procedure worked cogent Science antibody signal was stronger than that seen with well. indicating that the BT had lost its potency. Importantly. the the Santa Cruz antiserum.
In the midst of determining the conditions for staining sections failed BT was not beyond its with the immunofluorescence-amplified protocol. we noted that expiration date! 
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Discussion
The data presented here demonstrate that biotin amplification procedures can be used effectively to enhance immunocytochemical detection of the immediate early gene product CFOS. This was demonstrated through the use of thorough titrations of two commercial antisera against CFOS. Although the original lot of Oncogene Science antibody Ab-2 is no longer available, recent lots from this company have tested similarly in our laboratory. Titration of each primary antibody is an especially important element in using biotin amplification, just as it is in conventional immunocytochemistry. We recognize that it is common practice to attempt to use a primary antibody more concentrated than that recommended by the manufacturer to protect against variability of staining. However, this approach can fail with more sensitive techniques (see, e.g., Figures 2 and 3) . The scientist may conclude, incorrectly, that the primary antibody is worthless. In fact, most likely the opposite is true. We titrate all primary antibodies in the range of 1:lOOO to 1:100,000 in half-logarithmic increments. This approach allows US to more accurately monitor the usefulness of primary antibodies and to determine the most effective Concentration. The use of biotin amplification coupled with peroxidase staining confirmed the finding of Adams (11) that biotin amplification effectively reduces the concentration of primary antibody able to detect antigen. However, we noted that the use of nickel-enhanced DAB staining was highly successful with the biotin amplification immunoperoxidase procedure. This is in sharp contrast to Adams' conclusion that one is unable to incorporate metal-enhanced DAB into the biotin amplification. The chromogen solution in Adams' study was a DAB solution in 0.1 M phosphate buffer saturated with nickel and cobalt salts, and was filtered before use. It is possible that the quantities of reagents used by Adams were too concentrated to allow the metal to work in his system or that the inclusion of both nickel and cobalt salts impairs the staining reaction. Our nickel solutions were more dilute (0.250 g nickel sulfate and 0.002 g DAB in 40 ml sodium acetate solution) and did not include cobalt salts. Concentrations of BT used by Adams varied from 2-25 pl BT/ml, but his recommended working concentration was 10-25 BT/ml reaction mixture. After comprehensive testing of BT concentrations with the commercial kits, we found 1 pI BT/ml was optimal for immunoperoxidase staining; higher substrate volumes were effective with the synthesized BT. Also, unlike the findings in Adams' study, biotin amplification did not universally maintain low background staining. Systematic alteration of any of the reagents had little effect on improving this result when peroxidase staining procedures were used.
The greatest advantage of biotin amplification was seen with immunofluorescence staining. This technique was highly reproducible, enhanced the intensity of staining and reduced background staining. Both primary antibodies examined, Santa CNZ and Oncogene Science anti-cFos, were successful with biotin amplification and fluorescence visualization, although the former produced a signal of lower intensity. From our earlier studies with the conventional fluorescence procedures, detection of signals requires primary antibody concentrations 10-15 times more concentrated than those we use for the conventional immunoperoxidase techniques (4). Although in this study we used streptavidin-Texas Red as the fluorophore, we have also tested Bodipy-streptavidin and it, too, showed a very strong signal.
The antisera used in this study met our rigid criteria for acceptability before we learned of the biotin amplification method. We have also tested antibodies against a variety of antigens that do not produce high-quality signals with our conventional method. Only some of these antibodies improve with biotin amplification. Adams, in his study, noted the same. It is not yet possible with the immunoperoxidase staining and biotin amplification to predict with certainty the extent to which an antibody can be diluted and still achieve quality staining. In the immunofluorescence biotin amplification protocol, outcome is more predictable. Although we can envision how biotin amplification works on the basis of the biochemical reactions involved (15). its intricacies are not completely understood. Since all the steps up to the final visualization (DAB staining or incubation with streptavidin-fluorophore) are identical, the inconsistency must lie with the horseradish peroxidase staining reaction. It is possible that steric hindrance of the deposited stain prevents access of more substrate to the enzyme.
There can be instances in which both methods for biotin enhancement experience problems. The BT reaction could succeed one day, and the very next day fail. An important consideration when the method fails is the age of the BT solution. What determines the shelf-life of BT is unknown at this time. However. heightened awareness of an approaching expiration date is imperative. Studies are presently under way in our laboratory to determine the exact shelf-life of newly synthesized BT. 
